Combination of JAK inhibitor and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitor

摘要

The invention provides a pharmaceutical combination comprising: a) at least one agent selected from Bcr-Abl, Flt-3, FAK and RAF kinase inhibitors; and b) at least one JAK kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination.